JP7092744B2 - Ｆｃ含有タンパク質を精製する方法 - Google Patents

Ｆｃ含有タンパク質を精製する方法 Download PDF

Info

Publication number
JP7092744B2
JP7092744B2 JP2019503247A JP2019503247A JP7092744B2 JP 7092744 B2 JP7092744 B2 JP 7092744B2 JP 2019503247 A JP2019503247 A JP 2019503247A JP 2019503247 A JP2019503247 A JP 2019503247A JP 7092744 B2 JP7092744 B2 JP 7092744B2
Authority
JP
Japan
Prior art keywords
protein
antibody
region
elution buffer
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528255A (ja
JP2019528255A5 (enExample
Inventor
カウォーヤ，ジョン・ケイ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2019528255A publication Critical patent/JP2019528255A/ja
Publication of JP2019528255A5 publication Critical patent/JP2019528255A5/ja
Priority to JP2022096278A priority Critical patent/JP7411020B2/ja
Application granted granted Critical
Publication of JP7092744B2 publication Critical patent/JP7092744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
JP2019503247A 2016-07-22 2017-07-21 Ｆｃ含有タンパク質を精製する方法 Active JP7092744B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096278A JP7411020B2 (ja) 2016-07-22 2022-06-15 Ｆｃ含有タンパク質を精製する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22
US62/365,943 2016-07-22
PCT/US2017/043384 WO2018018011A2 (en) 2016-07-22 2017-07-21 Methods of purifying fc-containing proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096278A Division JP7411020B2 (ja) 2016-07-22 2022-06-15 Ｆｃ含有タンパク質を精製する方法

Publications (3)

Publication Number Publication Date
JP2019528255A JP2019528255A (ja) 2019-10-10
JP2019528255A5 JP2019528255A5 (enExample) 2020-07-27
JP7092744B2 true JP7092744B2 (ja) 2022-06-28

Family

ID=59656168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503247A Active JP7092744B2 (ja) 2016-07-22 2017-07-21 Ｆｃ含有タンパク質を精製する方法
JP2022096278A Active JP7411020B2 (ja) 2016-07-22 2022-06-15 Ｆｃ含有タンパク質を精製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096278A Active JP7411020B2 (ja) 2016-07-22 2022-06-15 Ｆｃ含有タンパク質を精製する方法

Country Status (12)

Country Link
US (1) US11312745B2 (enExample)
EP (1) EP3487867A2 (enExample)
JP (2) JP7092744B2 (enExample)
KR (2) KR102579850B1 (enExample)
CN (2) CN109563125B (enExample)
AU (2) AU2017298984B2 (enExample)
CA (2) CA3218290A1 (enExample)
IL (2) IL285146B (enExample)
MA (1) MA45721A (enExample)
MX (2) MX2019000903A (enExample)
SG (1) SG11201900573UA (enExample)
WO (1) WO2018018011A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501357A (ja) * 2018-09-21 2022-01-06 テネオバイオ， インコーポレイテッド ヘテロ二量体多重特異性抗体を精製するための方法
EP3863670A1 (en) * 2018-10-11 2021-08-18 Amgen Inc. Downstream processing of bispecific antibody constructs
JP2022517338A (ja) * 2019-01-16 2022-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体の断片化を特定及び定量する方法及びシステム
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
US12428470B2 (en) 2020-04-09 2025-09-30 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
EP4213958A1 (en) * 2020-09-16 2023-07-26 Waters Technologies Corporation Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
AU2022369694B2 (en) * 2021-10-19 2025-10-09 Alteogen, Inc Method for purifying fusion protein having igg fc domain
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116165290B (zh) * 2021-12-17 2025-06-27 复旦大学 一种抗体药物研发流程中工程细胞株的筛选方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
JP2011530606A (ja) 2008-08-14 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
JP2013505238A (ja) 2009-09-16 2013-02-14 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
JP2015511637A (ja) 2012-03-28 2015-04-20 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP1071769A1 (en) * 1998-04-16 2001-01-31 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
MX2007004437A (es) * 2004-10-22 2007-06-20 Amgen Inc Metodos para el repliegue de anticuerpos recombinantes.
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
EP1994054A4 (en) * 2006-01-06 2012-11-07 Amgen Inc METHODS AND SYSTEMS FOR ISOLATING TARGET MOLECULES OF COMPLEX COLUMN CHROMATOGRAPHY SOLUTIONS USING ELEMENTS CONTAINING ORGANIC SOLVENTS
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US10982250B2 (en) * 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
CN102382190B (zh) * 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
EP2657254A4 (en) 2010-12-24 2014-01-08 Asahi Kasei Medical Co Ltd PROCESS FOR IMMOBILIZING THE TEMPERATURE-REACTIVE PROTEIN A
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
JP6253584B2 (ja) 2012-08-27 2017-12-27 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
PE20160724A1 (es) * 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
JP2011530606A (ja) 2008-08-14 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
JP2013505238A (ja) 2009-09-16 2013-02-14 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
JP2015511637A (ja) 2012-03-28 2015-04-20 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Analytical Biochemistry，2005年，Vol.345, p.250-257

Also Published As

Publication number Publication date
IL264375A (en) 2019-02-28
CN109563125B (zh) 2022-08-09
AU2023222915A1 (en) 2023-09-21
AU2017298984B2 (en) 2023-08-31
CN109563125A (zh) 2019-04-02
WO2018018011A2 (en) 2018-01-25
JP2019528255A (ja) 2019-10-10
EP3487867A2 (en) 2019-05-29
IL285146B (en) 2022-09-01
IL285146A (en) 2021-08-31
MX2023006291A (es) 2023-06-13
US20190127418A1 (en) 2019-05-02
AU2017298984A1 (en) 2019-02-07
MA45721A (fr) 2019-05-29
CA3218290A1 (en) 2018-01-25
WO2018018011A3 (en) 2018-03-01
SG11201900573UA (en) 2019-02-27
JP7411020B2 (ja) 2024-01-10
KR102435801B1 (ko) 2022-08-25
US11312745B2 (en) 2022-04-26
JP2022120138A (ja) 2022-08-17
CN115925780B (zh) 2025-11-04
KR102579850B1 (ko) 2023-09-18
IL264375B (en) 2021-09-30
CN115925780A (zh) 2023-04-07
KR20190037247A (ko) 2019-04-05
KR20220120716A (ko) 2022-08-30
CA3031469A1 (en) 2018-01-25
CA3031469C (en) 2025-11-18
MX2019000903A (es) 2019-05-15

Similar Documents

Publication Publication Date Title
JP7411020B2 (ja) Ｆｃ含有タンパク質を精製する方法
JP5303092B2 (ja) タンパク質精製
US20160115193A1 (en) Novel purification of antibodies using hydrophobic interaction chromatography
JP6560673B2 (ja) ハイドロキシアパタイトクロマトグラフィーを用いた二重特異性抗体および二重特異性抗体生産副産物の分離法
US20130336957A1 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2012125735A1 (en) An integrated approach to the isolation and purification of antibodies
WO2013158279A1 (en) Protein purification methods to reduce acidic species
JP2008535913A (ja) タンパク質精製方法
CN107163101A (zh) 超载和洗脱层析
AU2018326458B2 (en) Method for purifying proteins
US11964998B2 (en) Method for purifying anti-IL-6 receptor antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220616

R150 Certificate of patent or registration of utility model

Ref document number: 7092744

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250